




Instance: composition-en-7829b4b361ffed64965739b1e7cc1436
InstanceOf: CompositionUvEpi
Title: "Composition for pioglitazone Package Leaflet"
Description:  "Composition for pioglitazone Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/12/755/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7829b4b361ffed64965739b1e7cc1436)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - pioglitazone"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Pioglitazone Actavis is and what it is used for </li>
<li>What you need to know before you take Pioglitazone Actavis </li>
<li>How to take Pioglitazone Actavis </li>
<li>Possible side effects </li>
<li>How to store Pioglitazone Actavis </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What pioglitazone is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What pioglitazone is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Pioglitazone Actavis contains pioglitazone. It is an anti-diabetic medicine used to treat type 2 
(non-insulin dependent) diabetes mellitus, when metformin is not suitable or has failed to work 
adequately. This is the diabetes that usually develops in adulthood. </p>
<p>Pioglitazone Actavis helps control the level of sugar in your blood when you have type 2 diabetes by 
helping your body make better use of the insulin it produces. Your doctor will check whether 
Pioglitazone Actavis is working 3 to 6 months after you start taking it. </p>
<p>Pioglitazone Actavis may be used on its own in patients who are unable to take metformin, and where 
treatment with diet and exercise has failed to control blood sugar or may be added to other therapies 
(such as metformin, sulphonylurea or insulin) which have failed to provide sufficient control of blood 
sugar. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take pioglitazone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take pioglitazone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Pioglitazone Actavis 
- if you are hypersensitive (allergic) to pioglitazone or any of the other ingredients of Pioglitazone 
Actavis (see section 6 for a list of ingredients). 
- if you have heart failure or have had heart failure in the past. 
- if you have liver disease. 
- if you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight loss, 
nausea or vomiting). 
- if you have or have ever had bladder cancer. 
- if you have blood in your urine that your doctor has not checked. </p>
<p>Warnings and precautions 
Talk to your doctor before you start to take this medicine:</p>
<ul>
<li>if you retain water (fluid retention) or have heart failure problems and in particular if you are 
over 75 years old. If you take anti-inflammatory medicines which can also cause fluid retention 
and swelling, you must also tell your doctor. </li>
<li>if you have a special type of diabetic eye disease called macular oedema (swelling of the back 
of the eye). </li>
<li>if you have cysts on your ovaries (polycystic ovary syndrome). There may be an increased 
possibility of becoming pregnant because you may ovulate again when you take Pioglitazone 
Actavis. If this applies to you, use appropriate contraception to avoid the possibility of an 
unplanned pregnancy. </li>
<li>if you have a problem with your liver or heart. Before you start taking Pioglitazone Actavis you 
will have a blood sample taken to check your liver function. This check may be repeated at 
intervals. Some patients with long-standing type 2 diabetes mellitus and heart disease or 
previous stroke who were treated with pioglitazone and insulin experienced the development of 
heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such 
as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). </li>
</ul>
<p>If you take Pioglitazone Actavis with other medicines for diabetes, it is more likely that your blood 
sugar could fall below the normal level (hypoglycaemia). </p>
<p>You may also experience a reduction in blood count (anaemia). </p>
<p>Broken bones 
A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. Your 
doctor will take this into account when treating your diabetes. </p>
<p>Children and adolescents 
Use in children under 18 years is not recommended. </p>
<p>Other medicines and Pioglitazone Actavis 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>You can usually continue to take other medicines whilst you are being treated with Pioglitazone 
Actavis. However, certain medicines are especially likely to affect the amount of sugar in your blood:</p>
<ul>
<li>gemfibrozil (used to lower cholesterol) </li>
<li>rifampicin (used to treat tuberculosis and other infections) 
Tell your doctor or pharmacist if you are taking any of these. Your blood sugar will be checked, and 
your dose of Pioglitazone Actavis may need to be changed. </li>
</ul>
<p>Pioglitazone Actavis with food and drink 
You may take your tablets with or without food. You should swallow the tablets with a glass of water. </p>
<p>Pregnancy and breastfeeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine. 
Your doctor will advise you to discontinue this medicine. </p>
<p>Driving and using machines 
Pioglitazone will not affect your ability to drive or use machines but take care if you experience 
abnormal vision. </p>
<p>Pioglitazone Actavis contains lactose monohydrate 
If you have been told by your doctor that you have intolerance to some sugars, contact your doctor 
before taking Pioglitazone Actavis. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take pioglitazone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take pioglitazone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The usual starting dose is one tablet of 15 mg or of 30 mg of pioglitazone to be taken once daily. Your 
doctor may increase the dose to a maximum of 45 mg once a day. Your doctor will tell you the dose to 
take. 
If you have the impression that the effect of Pioglitazone Actavis is too weak, talk to your doctor. </p>
<p>Pioglitazone Actavis can be taken with or without food. </p>
<p>When Pioglitazone Actavis is taken in combination with other medicines used to treat diabetes (such 
as insulin, chlorpropamide, glibenclamide, gliclazide, tolbutamide) your doctor will tell you whether 
you need to take a smaller dose of your medicines. </p>
<p>Your doctor will ask you to have blood tests periodically during treatment with Pioglitazone Actavis. 
This is to check that your liver is working normally. </p>
<p>If you are following a diabetic diet, you should continue with this while you are taking Pioglitazone 
Actavis. </p>
<p>Your weight should be checked at regular intervals; if your weight increases, inform your doctor. </p>
<p>If you take more Pioglitazone Actavis than you should 
If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a 
doctor or pharmacist immediately. Your blood sugar could fall below the normal level and can be 
increased by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or 
sugary fruit juice. </p>
<p>If you forget to take Pioglitazone Actavis 
Take Pioglitazone Actavis daily as prescribed. However if you miss a dose, just carry on with the next 
dose as normal. Do not take a double dose to make up for a forgotten tablet. 
For the 14, 28, 56, 84 and 98 tablets pack sizes, you can check the day on which you last took a tablet 
of Pioglitazone Actavis by referring to the calendar printed on the blister. </p>
<p>If you stop taking Pioglitazone Actavis<br />
Pioglitazone Actavis should be used every day to work properly. If you stop using Pioglitazone 
Actavis, your blood sugar may go up. Talk to your doctor before stopping this treatment. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>In particular, patients have experienced the following serious side effects: </p>
<p>Heart failure has been experienced commonly (up to 1 in 10 people) in patients taking pioglitazone in 
combination with insulin. Symptoms are unusual shortness of breath or rapid increase in weight or 
localised swelling (oedema). If you experience any of these, especially if you are over the age of 65, 
seek medical advice straight away. </p>
<p>Bladder cancer has been experienced uncommonly (up to 1 in 100 people) in patients taking 
pioglitazone. Signs and symptoms include blood in your urine, pain when urinating or a sudden need 
to urinate. If you experience any of these, talk to your doctor as soon as possible. </p>
<p>Localised swelling (oedema) has also been experienced very commonly in patients taking 
pioglitazone in combination with insulin. If you experience this side effect, talk to your doctor as soon 
as possible. </p>
<p>Broken bones have been reported commonly (up to 1 in 10 people) in female patients taking 
pioglitazone and have also been reported in male patients (frequency cannot be estimated from the 
available data) taking pioglitazone. If you experience this side effect, talk to your doctor as soon as 
possible. </p>
<p>Blurred vision due to swelling (or fluid) at the back of the eye (frequency not known) has also been 
reported in patients taking pioglitazone. If you experience this symptom for the first time, talk to your 
doctor as soon as possible. Also, if you already have blurred vision and the symptom gets worse, talk 
to your doctor as soon as possible. </p>
<p>Allergic reactions have been reported (frequency not known) in patients taking Pioglitazone Actavis. 
If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat 
that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor 
as soon as possible. </p>
<p>The other side effects that have been experienced by some patients taking pioglitazone: </p>
<p>Common (may affect up to 1 in 10 people) 
- respiratory infection 
- abnormal vision 
- weight gain 
- numbness </p>
<p>Uncommon (may affect up to 1 in 100 people) 
- inflammation of the sinuses (sinusitis) 
- difficulty sleeping (insomnia) </p>
<p>Not known (frequency cannot be estimated from the available data) 
- increase in liver enzymes 
- allergic reactions </p>
<p>The other side effects that have been experienced by some patients when pioglitazone is taken with 
other antidiabetic medicines are: </p>
<p>Very common (may affect more than 1 in 10 people) 
- decreased blood sugar (hypoglycaemia) </p>
<p>Common (may affect up to 1 in 10 people) 
- headache 
- dizziness 
- joint pain 
- impotence 
- back pain 
- shortness of breath 
- small reduction in red blood cell count 
- flatulence (wind) </p>
<p>Uncommon (may affect up to 1 in 100 people) 
- sugar in urine, proteins in urine 
- increase in enzymes 
- spinning sensation (vertigo) 
- sweating 
- tiredness 
- increased appetite </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store pioglitazone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store pioglitazone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep out of the sight and reach of children. </p>
<p>Do not use Pioglitazone Actavis after the expiry date which is stated on the carton and the blister pack 
after the word  EXP . The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage precautions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Pioglitazone Actavis contains 
- The active substance is pioglitazone.  </p>
<p>Each tablet contains 15 mg, 30 mg or 45 mg of pioglitazone (as hydrochloride). </p>
<p>Each tablet contains 15 mg of pioglitazone (as hydrochloride).  </p>
<p>Each tablet contains 30 mg of pioglitazone (as hydrochloride). </p>
<p>Each tablet contains 45 mg of pioglitazone (as hydrochloride). 
- The other ingredients are lactose monohydrate, hydroxypropylcellulose, carmellose calcium and 
magnesium stearate. </p>
<p>What Pioglitazone Actavis looks like and contents of the pack 
Pioglitazone Actavis 15 mg tablets are white, round, flat, bevelled, 5.5 mm in diameter and engraved 
with  TZ15  on one side. 
Pioglitazone Actavis 30 mg tablets are white, round, flat, bevelled, 7 mm in diameter and engraved 
with  TZ30  on one side. 
Pioglitazone Actavis 45 mg tablets are white, round, flat, bevelled, 8 mm in diameter and engraved 
with  TZ45  on one side. </p>
<p>The tablets are supplied in aluminium blister packs of 14, 28, 30, 50, 56, 84, 90, 98 and 100 tablets.<br />
The packs with 14, 28, 56, 84 and 98 tablets contain blisters with abbreviations for days of the week 
printed on the blister (Mon, Tue, Wed, Thu, Fri, Sat, Sun). </p>
<p>Not all the pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<p>Marketing Authorisation Holder 
Actavis Group PTC ehf.<br />
Dalshraun 1 
220 Hafnarfj r ur 
Iceland </p>
<p>Manufacturer 
Actavis Ltd. 
BLB 015-016 Bulebel Industrial Estate 
Zejtun ZTN 3Malta </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Actavis Group PTC ehf. 
IJsland/Islande/Island 
T l/Tel: +354 5503Lietuva 
UAB Teva Baltics 
Tel: +370 52660  </p>
<p>: +359 24899Luxembourg/Luxemburg 
Actavis Group PTC ehf. 
Islande/Island 
T l/Tel: +354 5503 esk  republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007Magyarorsz g 
Teva Gy gyszergy r Zrt. 
Tel: +36 12886Danmark 
Teva Denmark A/S 
Tlf: +45 44985Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407Deutschland 
Actavis Group PTC ehf. 
Island 
Tel: +354 5503Nederland 
Actavis Group PTC ehf. 
IJsland 
Tel: +354 5503Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610Norge 
Teva Norway AS 
Tlf: +47 66775<br />
Specifar A.B.E.E. 
 : +30 2118805 sterreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970Espa a 
Actavis Group PTC ehf. 
Islandia 
Tel: +354 5503Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459France 
Actavis Group PTC ehf. 
Islande 
T l: +354 5503Portugal 
Actavis Group PTC ehf. 
Isl ndia 
Tel: +354 5503Hrvatska 
Pliva Hrvatska d.o.o.<br />
Tel: +385 13720Rom nia 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 sland 
Actavis Group PTC ehf. 
S mi: +354 5503Slovensk  republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267Italia 
Actavis Group PTC ehf. 
Islanda 
Tel: +354 5503Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805<br />
Specifar A.B.E.E. </p>
<p>: +30 2118805Sverige 
Teva Sweden AB 
Tel: +46 42121Latvija 
UAB Teva Baltics fili le Latvij<br />
Tel: +371 67323United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407This leaflet was last revised in {MM/YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-7829b4b361ffed64965739b1e7cc1436
InstanceOf: CompositionUvEpi
Title: "Composition for pioglitazone Package Leaflet"
Description:  "Composition for pioglitazone Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/12/755/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp7829b4b361ffed64965739b1e7cc1436)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - pioglitazone"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Pioglitazon Actavis. 
3. Sådan skal du tage Pioglitazon Actavis 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What pioglitazone is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What pioglitazone is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Pioglitazon Actavis indeholder pioglitazon. Det er en antidiabetisk medicin, der anvendes til 
behandling af type 2-diabetes mellitus (ikke-insulinkrævende sukkersyge), når metformin ikke er 
egnet eller ikke har haft tilstrækkelig virkning. Dette er den diabetesform, der normalt udvikler sig i 
voksenalderen.  </p>
<p>Pioglitazon Actavis hjælper med at kontrollere sukkerniveauet i dit blod, hvis du har type 2-
diabetes, ved at hjælpe din krop til bedre at udnytte den insulin, kroppen producerer. Din læge vil 
undersøge om Pioglitazon Actavis virker 3 til 6 måneder efter du starter med at tage det. </p>
<p>Pioglitazon Actavis kan anvendes alene til patienter, som ikke er i stand til at tage metformin, og 
hos hvem diæt og motion ikke har været i stand til at kontrollere blodsukkeret, eller det kan 
anvendes som supplement til andre lægemidler (såsom metformin, sulfonylurinstof eller insulin), 
hvis dette ikke har været i stand til at kontrollere blodsukkeret tilstrækkeligt. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take pioglitazone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take pioglitazone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Pioglitazon Actavis 
- hvis du er allergisk over for pioglitazon, eller et af de øvrige indholdsstoffer i Pioglitazon 
Actavis (angivet i punkt 6), hvis du lider af hjertesvigt eller tidligere har haft hjertesvigt. 
- hvis du en har leversygdom. 
- hvis du har haft diabetisk ketoacidose (en komplikation ved diabetes, der giver hurtigt vægttab, 
kvalme eller opkastning). 
- hvis du har eller har haft blærekræft 
- hvis du har blod i urinen som din læge endnu ikke har undersøgt. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du tager Pioglitazon Actavis:</p>
<ul>
<li>hvis du har vand i kroppen (ødemer) eller har problemer med hjertesvigt, specielt hvis du er 
over 75 år. Hvis De tager antiinflammatoriske (betændelseshæmmende) lægemidler, som også 
kan forårsage væskeophobning og hævelse, skal De også fortælle det til lægen. </li>
<li>hvis du lider af en særlig diabetisk øjenlidelse, som hedder makulaødem (væskeansamling i det 
bagerste af øjet). </li>
<li>hvis du har cyster på æggestokkene (polycystisk ovariesyndrom). Der kan være større 
sandsynlighed for at blive gravid, fordi du kan få ægløsning igen, når du tager Pioglitazon 
Actavis. Hvis dette er relevant for dig, skal du anvende sikker prævention, så du undgår uønsket 
graviditet. </li>
<li>hvis du har problemer med lever eller hjerte. Før du begynder at tage Pioglitazon Actavis, vil du 
få taget en blodprøve til kontrol af leverfunktionen. Denne kontrol skal måske udføres løbende. 
Nogle patienter, som har haft type 2-diabetes i mange år og samtidig har hjertesygdom, eller 
som har haft et slagtilfælde, har udviklet hjertesvigt, når de blev behandlet med pioglitazon og 
insulin samtidig. Kontakt lægen hurtigst muligt, hvis du oplever tegn på hjertesvigt såsom 
usædvanlig åndenød, hurtig vægtstigning eller lokale væskeansamlinger (ødemer). </li>
</ul>
<p>Hvis du tager Pioglitazon Actavis sammen med anden diabetesmedicin, er der en større risiko for, at 
dit blodsukker falder til under det normale niveau (hypoglykæmi). </p>
<p>Du kan også få blodmangel (anæmi).<br />
Knoglebrud 
Der er set et øget antal knoglebrud hos patienter, særligt kvinder, der tog pioglitazon. Din læge vil tage 
dette i betragtning ved planlægning af din behandling. </p>
<p>Børn og unge 
Brug hos børn under 18 år anbefales ikke. </p>
<p>Brug af anden medicin sammen med Pioglitazon Actavis 
Fortæl lægen eller apotekspersonalet, hvis du bruger anden medicin eller har gjort det for nylig. </p>
<p>Du kan normalt blive ved med at tage anden medicin, mens du får Pioglitazon Actavis. Visse typer 
medicin er dog særlig tilbøjelige til at påvirke blodsukkeret:</p>
<ul>
<li>gemfibrozil (til at sænke kolesteroltallet) </li>
<li>rifampicin (mod tuberkulose og andre infektioner) 
Fortæl det til lægen eller på apoteket, hvis du får et af disse lægemidler. Du vil få kontrolleret<br />
blodsukkeret for at se, om du skal have ændret dosis af Pioglitazon Actavis. </li>
</ul>
<p>Brug af Pioglitazon Actavis sammen med mad og drikke 
Du kan tage Pioglitazon Actavis med eller uden et måltid. Du skal sluge tabletterne med et glas vand. </p>
<p>Graviditet og amning 
Hvis du er gravid eller ammer, har mistanke om at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel. 
Din læge vil råde dig til at stoppe med at tage denne medicin. </p>
<p>Trafik- og arbejdssikkerhed 
Pioglitazon vil ikke påvirke din evne til at køre bil eller arbejde med maskiner. Vær forsigtig, hvis du 
får synsforstyrrelser. </p>
<p>Pioglitazon Actavis indeholder lactosemonohydrat<br />
Kontakt lægen, før du tager denne medicin, hvis lægen har fortalt dig, at du ikke tåler visse 
sukkerarter. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take pioglitazone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take pioglitazone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er De i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Den normale start dosis er 1tablet på 15 mg eller 30 mg pioglitazon en gang daglig. Deres læge kan 
øge dosis til maksimalt 45 mg en gang daglig. Deres læge vil fortælle Dem hvilken dosis De skal tage. 
Tal med lægen, hvis du har indtryk af, at effekten af Pioglitazon Actavis er for svag. </p>
<p>Pioglitazon Actavis kan tages med eller uden et måltid. </p>
<p>Når Pioglitazon Actavis tages sammen med andre lægemidler, der anvendes til behandling af 
sukkersyge (f.eks. insulin, chlorpropamid, glibenclamid, gliclazid, tolbutamid), vil din læge give dig 
besked på, om du skal tage en mindre dosis af lægemidlerne. </p>
<p>Din læge vil bede dig om at få taget blodprøver periodevis, mens du er i behandling med Pioglitazon 
Actavis. Dette sker for at checke, at din lever fungerer normalt. </p>
<p>Hvis du følger en diabetesdiæt, skal du fortsætte med denne, mens du tager Pioglitazon Actavis.<br />
Din vægt bør checkes med jævne mellemrum; hvis din vægt stiger, underret da din læge. </p>
<p>Hvis du har taget for mange Pioglitazon Actavis filmovertrukne tabletter 
Kontakt straks lægen, skadestuen eller apoteket, hvis du ved en fejltagelse har taget for mange 
tabletter, eller hvis en anden eller et barn tager din medicin. 
Blodsukkeret kan derved falde til under det normale niveau og kan bringes til at stige igen ved 
indtagelse af sukker. Det anbefales, at du altid medbringer sukkerknalder, slik, kiks eller sød 
frugtjuice. </p>
<p>Hvis du har glemt at tage Pioglitazon Actavis 
Tag Pioglitazon Actavis dagligt som foreskrevet. Hvis du glemmer en dosis, skal du dog bare fortsætte 
med den næste dosis som normalt. Du må ikke tage en dobbeltdosis som erstatning for den glemte 
dosis. 
For tabletterne i 14, 28, 56, 84 og 98-styks pakningerne kan du tjekke på hvilken ugedag, du sidst tog 
din tablet Pioglitazon Actavis ved at se på kalenderen trykt på blisterpakningen. </p>
<p>Hvis du holder op med at tage Pioglitazon Actavis 
For at opnå den ønskede virkning skal du tage Pioglitazon Actavis hver dag. Hvis du holder op med at 
tage Pioglitazon Actavis, kan dit blodsukker stige. Tal med lægen, før du stopper behandlingen. </p>
<p>Spørg lægen eller på apoteket, hvis der er noget du er i tvivl om. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Patienter har især oplevet følgende alvorlige bivirkninger: </p>
<p>Patienter der tager pioglitazon samtidig med insulin har almindeligvis oplevet hjertesvigt (op til 1 ud 
af 10 personer). Symptomerne er stakåndethed, hurtig vægtforøgelse eller lokal hævelse (ødem). Hvis 
du oplever nogle af disse symptomer, især hvis du er over 65 år, skal du søge lægehjælp med det 
samme. </p>
<p>Patienter der tager pioglitazon har ikke almindeligvis oplevet blærekræft (op til 1 ud af 100 personer). 
Tegn og symptomer er blod i urinen, smerter ved vandladning eller pludselig vandladningstrang. Hvis 
du oplever nogle af disse symptomer skal du fortælle det til lægen hurtigst muligt. </p>
<p>Patienter der tager pioglitazon samtidig med insulin har også meget almindeligt oplevet lokale 
hævelser (ødemer). Hvis du får denne bivirkning skal du fortælle det til lægen hurtigst muligt. </p>
<p>Kvindelige patienter der tager pioglitazon har almindeligvis rapporteret om knoglebrud (op til 1 ud af 
10 personer), og det er ligeledes indberettet hos mandlige patienter (hyppighed kan ikke vurderes ud 
fra de tilgængelige data). Hvis du får denne bivirkning skal du fortælle det til lægen hurtigst muligt. </p>
<p>Yderligere har patienter der tager pioglitazon rapporteret om sløret syn på bagsiden af øjet pga. 
hævelse (eller væske) (hyppigheden kendes ikke). Hvis du for første gang får dette symptom skal du 
tale med lægen hurtigst muligt. Det samme gælder, hvis du allerede har sløret syn og symptomerne 
forværres. </p>
<p>Der er rapporteret om allergiske reaktioner (hyppighed ikke kendt) hos patienter, der tager pioglitazon. 
Hvis du får en alvorlig allergisk reaktion, herunder nældefeber og hævelse af ansigtet, læber, tunge 
eller svælg, der kan forårsage vejrtræknings- eller synkebesvær, skal du afbryde behandlingen og 
kontakte en læge så hurtigt som muligt. </p>
<p>Andre bivirkninger oplevet af patienter der tager pioglitazon: </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) 
- luftvejsinfektion 
- synsforstyrrelser 
- vægtforøgelse 
- følelsesløshed </p>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) 
- bihulebetændelse (sinusitis) 
- søvnløshed (insomi) </p>
<p>Ikke kendt (hyppigheden kan ikke estimeres ud fra tilgængelige data) 
- forhøjede leverenzymer 
- allergiske reaktioner </p>
<p>Andre bivirkninger oplevet af patienter når pioglitazon tages samtidig med anden diabetesmedicin er: </p>
<p>Meget almindelige (kan forekomme hos mere end 1 ud af 10 personer) 
- lavt blodsukker (hypoglykæmi) </p>
<p>Almindelige (kan forekomme hos op til 1 ud af 10 personer) 
- hovedpine 
- svimmelhed 
- ledsmerter 
- impotens 
- rygsmerter 
- stakåndethed 
- mindre fald i antallet af røde blodlegemer 
- flatulens (luftafgang fra tarmen) </p>
<p>Ikke almindelige (kan forekomme hos op til 1 ud af 100 personer) 
- sukker i urinen, proteiner i urinen 
- forhøjet enzymtal 
- svimmelhed, hvor alting drejer rundt (vertigo) 
- svedudbrud 
- træthed 
- øget appetit </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store pioglitazone"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store pioglitazone"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke Pioglitazon Actavis efter den udløbsdato, der står på pakningen af "EXP". Udløbsdatoen er 
den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Pioglitazon Actavis indeholder:</p>
<ul>
<li>
<p>Det aktive stof er pioglitazon. 
Hver tablet indeholder 15 mg, 30 mg eller 45 mg pioglitazon (som hydrochlorid). 
Hver tablet indeholder 15 mg pioglitazon (som hydrochlorid). 
Hver tablet indeholder 30 mg pioglitazon (som hydrochlorid). 
Hver tablet indeholder 45 mg pioglitazon (som hydrochlorid). </p>
</li>
<li>
<p>De øvrige indholdsstoffer er lactosemonohydrat, hydroxypropylcellulose, carmellosecalcium og 
magnesiumstearat. </p>
</li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Pioglitazon Actavis 15 mg tabletter er hvide, runde, flade, skråkantede, 5,5 mm i diameter og mærket 
med "TZ15" på den ene side. 
Pioglitazon Actavis 30 mg tabletter er hvide, runde, flade, skråkantede, 7 mm i diameter og mærket 
med "TZ30" på den ene side. 
Pioglitazon Actavis 45 mg tabletter er hvide, runde, flade, skråkantede, 8 mm i diameter og mærket 
med "TZ45" på den ene side. </p>
<p>Tabletterne leveres i aluminiumblisterpakninger a 14, 28, 30, 50, 56, 84, 90, 98 og 100 tabletter. 
Pakningerne med 14, 28, 56, 84 og 98 tabletter indeholder blisterpakninger med forkortelser for 
ugedagene trykt på blisterpakningen (Man., Tirs., Ons., Tors., Fre., Lør., Søn.). 
Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>Indehaver af markedsføringstilladelsen 
Actavis Group PTC ehf. 
Dalshraun 1 
220 Hafnarfjördur 
Island </p>
<p>Fremstiller 
Actavis Ltd. 
BLB 015-016 Bulebel Industrial Estate 
Zejtun ZTN 3Malta </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen. </p>
<p>België/Belgique/Belgien 
Actavis Group PTC ehf. 
IJsland/Islande/Island 
Tél/Tel: +354 5503 
Lietuva 
UAB Teva Baltics 
Tel: +370 52660 
България 
Тева Фарма ЕАД 
Тел: +359 24899 
Luxembourg/Luxemburg 
Actavis Group PTC ehf. 
Islande/Island 
Tél/Tel: +354 5503 
Česká republika 
Teva Pharmaceuticals CR, s.r.o. 
Tel: +420 251007 
Magyarország 
Teva Gyógyszergyár Zrt. 
Tel: +36 12886 
Danmark 
Teva Denmark A/S 
Tlf: +45 44985 
Malta 
Teva Pharmaceuticals Ireland 
L-Irlanda 
Tel: +44 2075407 
Deutschland 
Actavis Group PTC ehf. 
Island 
Tel: +354 5503 
Nederland 
Actavis Group PTC ehf. 
IJsland 
Tel: +354 5503 
Eesti 
UAB Teva Baltics Eesti filiaal 
Tel: +372 6610 
Norge 
Teva Norway AS 
Tlf: +47 66775 
Ελλάδα 
Specifar A.B.E.E. 
Τηλ: +30 2118805 
Österreich 
ratiopharm Arzneimittel Vertriebs-GmbH 
Tel: +43 1970 
España 
Actavis Group PTC ehf. 
Islandia 
Tel: +354 5503 
Polska 
Teva Pharmaceuticals Polska Sp. z o.o. 
Tel: +48 223459 
France 
Actavis Group PTC ehf. 
Islande 
Tél: +354 5503 
Portugal 
Actavis Group PTC ehf. 
Islândia 
Tel: +354 5503 
Hrvatska 
Pliva Hrvatska d.o.o.<br />
Tel: +385 13720 
România 
Teva Pharmaceuticals S.R.L. 
Tel: +40 212306 
Ireland 
Teva Pharmaceuticals Ireland 
Tel: +44 2075407 
Slovenija 
Pliva Ljubljana d.o.o. 
Tel: +386 15890 
Ísland 
Actavis Group PTC ehf. 
Sími: +354 5503 
Slovenská republika 
TEVA Pharmaceuticals Slovakia s.r.o. 
Tel: +421 257267 
Italia 
Actavis Group PTC ehf. 
Islanda 
Tel: +354 5503 
Suomi/Finland 
Teva Finland Oy 
Puh/Tel: +358 201805 
Κύπρος 
Specifar A.B.E.E. 
Ελλάδα 
Τηλ: +30 2118805 
Sverige 
Teva Sweden AB 
Tel: +46 42121 
Latvija 
UAB Teva Baltics filiāle Latvijā 
Tel: +371 67323 
United Kingdom (Northern Ireland) 
Teva Pharmaceuticals Ireland 
Ireland 
Tel: +44 2075407 </p>
<p>Denne indlægsseddel blev senest ændret { MM/ÅÅÅÅ } </p>
<p>Du kan finde yderligere information om Pioglitazon Actavis på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-7829b4b361ffed64965739b1e7cc1436
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for pioglitazone Package Leaflet for language en"
Description: "ePI document Bundle for pioglitazone Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-7829b4b361ffed64965739b1e7cc1436"
* entry[0].resource = composition-en-7829b4b361ffed64965739b1e7cc1436

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp7829b4b361ffed64965739b1e7cc1436"
* entry[=].resource = mp7829b4b361ffed64965739b1e7cc1436
                            
                    
Instance: bundlepackageleaflet-da-7829b4b361ffed64965739b1e7cc1436
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for pioglitazone Package Leaflet for language da"
Description: "ePI document Bundle for pioglitazone Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-7829b4b361ffed64965739b1e7cc1436"
* entry[0].resource = composition-da-7829b4b361ffed64965739b1e7cc1436

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp7829b4b361ffed64965739b1e7cc1436"
* entry[=].resource = mp7829b4b361ffed64965739b1e7cc1436
                            
                    



Instance: mp7829b4b361ffed64965739b1e7cc1436
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Pioglitazone Actavis 15 mg tablets"
Description: "Pioglitazone Actavis 15 mg tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/12/755/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Pioglitazone Actavis 15 mg tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 7829b4b361ffed64965739b1e7cc1436ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "pioglitazone"

* status = #current
* mode = #working

* title = "List of all ePIs associated with pioglitazone"

* subject = Reference(mp7829b4b361ffed64965739b1e7cc1436)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#pioglitazone "pioglitazone"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-7829b4b361ffed64965739b1e7cc1436) // pioglitazone en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-7829b4b361ffed64965739b1e7cc1436) // pioglitazone da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-7829b4b361ffed64965739b1e7cc1436
InstanceOf: List

* insert 7829b4b361ffed64965739b1e7cc1436ListRuleset
    